NewsRoom Articles - Page 30 of 48

FridayFeb 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expecting Additional Growth in 2023, Including IND Filing and IND Clinical Study

In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28 patents granted and roughly 50 patent applications pending worldwide For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human…

ThursdayFeb 09, 2023 10:30 am

Nemaura Medical, Inc. (NASDAQ: NMRD) Featured in Coverage of The MicroCap Rodeo’s 3rd Annual Winter Wonderful and Best Ideas Investor Conference

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT(R) to the U.S. FDA. proBEAT(TM) combines non-invasive glucose data processed using artificial intelligence and a digital healthcare…

WednesdayFeb 08, 2023 9:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending Speaking during a late…

MondayFeb 06, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year

2022 saw Lexaria introduce its patented DehydraTECH(TM) technology to world-leading collaborators while also exploring DehydraTECH-CBD for the potential treatment of hypertension It also saw success in its research for the potential treatment of conditions such as epilepsy, making the year Lexaria’s most active one yet Significant progress was made on key objectives in 2022, a feat which the company plans to capitalize on and leverage to scale up the commercial execution of its technology in 2023 To facilitate this, Lexaria has brought on board Julian Gangolli, former President of GW Pharmaceuticals USA, as a strategic advisor. Chris Bunka, Lexaria’s CEO,…

FridayJan 27, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023

Lexaria Bioscience recently released its 2023 annual letter from CEO Chris Bunka, providing a strategic update to all stakeholders The letter highlights the key milestones achieved in calendar 2022, outlines expectations for calendar 2023, and indicates why Chris Bunka expects 2023 to be the company’s best year so far 1In calendar 2023, Lexaria expects to attain FDA registration for an investigational new drug (“IND”) program and commence Phase 1(b) clinical study evaluating the safety and tolerability of DehydraTECH(TM)-processed CBD as a treatment for hypertension The company will also be pursuing commercial relationships in 2023 even as its R&D continues to…

WednesdayJan 25, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream…

MondayJan 23, 2023 10:30 am

Cepton, Inc. (NASDAQ: CPTN) Kicks off the New Year; Launches Vista(R)-X120 Plus — Ultra-Slim, Next-Gen Lidar for ADAS and Automotive Driving Applications

Built upon its predecessor–Vista-X90 lidar–that is being used in Cepton's flagship ADAS lidar program with GM and Koito, the Vista-X120 Plus is designed to significantly enhance lidar performance without compromising reliability, size, power efficiency, and cost Vista-X120 Plus advances the company's vision of enabling safe and autonomous transportation for everyone through mass-market lidar adoption. As a member of the Lidar Coalition, Cepton showcased its new product and a comprehensive portfolio of its lidar solutions at CES 2023, one of the most influential tech events in the world; the company demonstrated its adaptive 3D perception and simulations featuring a Chevy Silverado…

WednesdayJan 18, 2023 9:00 am

Vision Energy Corp. (VENG) Announces Incorporation of New Dutch Subsidiaries to Accommodate Strategic Initiatives for Prospective Partners

Vision Energy has announced the incorporation of Vision Hydrogen BV as a project development company for its planned Ammonia Cracking Facility for back-cracking imported green ammonia into hydrogen gas as a service On December 2, 2022, Vision entered a Memorandum of Understanding with Linde Engineering with a mutual interest to participate in co-investment, development, and operations associated with hydrogen production through ammonia back-cracking Vision Energy has also incorporated “Evolution Terminals Operating BV,” a dedicated entity that will jointly own and operate logistics infrastructure The company’s Green Energy Hub is positioned to be the first terminal in Europe focused on green…

ThursdayJan 12, 2023 11:15 am

Vision Energy Corp. (VENG) Files Application Initiating Formal Environmental Permit Assessment Process for Green Energy Hub Terminal Development Project in the Netherlands

Vision Energy is pioneering a Green Energy Hub terminal development project for the importation, storage, handling, and distribution of low-carbon renewable fuels and hydrogen carriers, including green ammonia, methanol, and biofuels The company intends to construct the development in phases, with Phase 1 accommodating 400,000 cubic meters of renewable liquid bulk storage and supporting infrastructure Vision Energy has engaged environmental experts and specialist Netherlands-based consultancy firms to undertake detailed studies to support final permit applications for the development Vision Energy (OTCQB: VENG), through its wholly owned subsidiary Evolution Terminals BV, is in the advanced stages of planning the construction of…

WednesdayJan 11, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancers This patent inches Lexaria closer to taking advantage of the cosmeceuticals market, projected…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000